PMID- 30106142
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190109
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 18
IP  - 4
DP  - 2018 Oct
TI  - Overexpression of KLF5 inhibits puromycin‑induced apoptosis of podocytes.
PG  - 3843-3849
LID - 10.3892/mmr.2018.9366 [doi]
AB  - Diabetic nephropathy (DN) is one of the most common microvascular complications 
      associated with diabetes mellitus (DM); the incidence has been predicted to reach 
      7.7% by 2030 on a global scale. Kruppel‑like factor 5 (KLF5) is involved in 
      numerous important biological processes; however, the potential effects of KLF5 
      on podocytes in patients with diabetic nephrotic (DN) have not yet been 
      investigated. In the present study, synaptopodin expression in podocytes was 
      investigated using an immunofluorescence assay. Following this, the proliferation 
      of podocytes was investigated using an MTT assay. In addition, KLF5 was 
      overexpressed in podocytes, and cell cycle arrest and apoptosis was subsequently 
      investigated using flow cytometry. Western blotting and reverse 
      transcription‑quantitative polymerase chain reaction assays were performed to 
      detect the expression levels of genes involved in the cell cycle and apoptosis, 
      and the extracellular signal‑regulated protein kinase (ERK)/p38 mitogen‑activated 
      protein (MAP) kinase pathway. The results demonstrated that treatment with 
      puromycin aminonucleoside (PAN) suppressed the proliferation of podocytes in a 
      dose‑ and time‑dependent manner, and overexpression of KLF5 induced cell cycle 
      arrest of podocytes regulated by PAN. Furthermore, overexpression of KLF5 was 
      revealed to have inhibited PAN‑induced apoptosis of podocytes, and that 
      overexpression of KLF5 suppressed the ERK/p38 MAP kinase pathway in podocytes 
      induced by PAN. Therefore, the results of the present study suggested that KLF5 
      may represent a potential therapeutic target for treatment of patients with DN.
FAU - Li, Yang
AU  - Li Y
AD  - Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong 
      250012, P.R. China.
FAU - Sui, Xiaoni
AU  - Sui X
AD  - Department of Nephrology, Qingdao Municipal Hospital, Qingdao, Shandong 266011, 
      P.R. China.
FAU - Hu, Xueqing
AU  - Hu X
AD  - Department of Nephrology, Qingdao Municipal Hospital, Qingdao, Shandong 266011, 
      P.R. China.
FAU - Hu, Zhao
AU  - Hu Z
AD  - Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong 
      250012, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180809
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Klf5 protein, mouse)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 58-60-6 (Puromycin Aminonucleoside)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Cell Division/drug effects
MH  - Cell Line
MH  - Diabetic Nephropathies/chemically induced/genetics/metabolism/pathology
MH  - Kruppel-Like Transcription Factors/*genetics
MH  - MAP Kinase Signaling System/drug effects
MH  - Mice
MH  - Podocytes/*cytology/*drug effects/metabolism/pathology
MH  - Puromycin Aminonucleoside/*adverse effects
MH  - *Up-Regulation
PMC - PMC6131625
EDAT- 2018/08/15 06:00
MHDA- 2019/01/10 06:00
PMCR- 2018/08/09
CRDT- 2018/08/15 06:00
PHST- 2018/01/18 00:00 [received]
PHST- 2018/06/28 00:00 [accepted]
PHST- 2018/08/15 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
PHST- 2018/08/15 06:00 [entrez]
PHST- 2018/08/09 00:00 [pmc-release]
AID - mmr-18-04-3843 [pii]
AID - 10.3892/mmr.2018.9366 [doi]
PST - ppublish
SO  - Mol Med Rep. 2018 Oct;18(4):3843-3849. doi: 10.3892/mmr.2018.9366. Epub 2018 Aug 
      9.